AbbVie is recommended as a buy despite recent reductions in EPS guidance, which are attributed to normal in-process research and development (IPR&D) and milestone expenses rather than operational issues. The company reported a strong Q4 with 10% revenue growth and a 38.3% adjusted operating margin, with earnings growth outpacing sales. Positive trial results for drugs Skyrizi and ABBV-295 highlight the strength of AbbVie's pipeline, helping to offset competitive and regulatory challenges. With a forward price-to-earnings ratio of 13.85, AbbVie's stock valuation is at multiyear lows, presenting an attractive risk/reward profile for long-term growth.
SkinMedica, part of Allergan Aesthetics under AbbVie, has launched a Regenerative Science Advisory Board composed of leading skin health experts to guide future innovation. The company also expanded its R&D facility in Irvine, California, integrating...
Big pharmaceutical companies are confronting a $300 billion loss in drug patents by 2030, prompting a surge in acquisitions of mid-size biotech firms with promising drug pipelines. In 2026, biopharma deal values are expected to exceed $250 billion, t...
